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Background: The prescription of the oral anticoagulant rivaroxaban to prevent thromboembolic episodes
associated with orthopaedic surgery has dramatically increased since it was introduced. Rivaroxaban is beeing
prescribed although recent in-vitro studies revealed that it impaired osteoblast metabolism. In this study we
analysed the effect of rivaroxaban on fracture healing in a rat femur fracture model.
Methods: Femur fractures were created by a 3-point-bending device in 48 Wistar rats and subsequently stabilized
by intramedullary nailing. After the surgical procedure animals were randomised into four groups. Two groups were
fed with 3 mg rivaroxaban per kg body weight per day and two control groups were fed with chow only. Animals
were euthanized 28 or 49 days after surgical procedure. Femurs underwent undecalcified histologic staining micro
CT scanning and biomechanical testing. The statistical significance was evaluated using one-way Anova with
Bonferroni correction.
Results: Micro CT-scans revealed significantly increased volume of bone tissue in the fracture zone between day 28
and 49. During the same time callus volume decreased significantly. Comparing the fracture zone of the rivaroxaban
group to the control group the treated group revealed a larger callus and a marginal increase of the tissue mineral
density. The torsional rigidity was not influenced by the treatment of rivaroxaban.
Conclusion: In the present study we were able to demonstrate that rivaroxaban does not impair fracture healing in
a rat femur fracture model. Considering the fact that low molecular weight heparins delay fracture healing
significantly, rivaroxaban might be an improved alternative.Background
Thrombembolic complications constitute a main cause
of mortality after fractures of the lower limb. Several
studies document that without thromboprophylaxis the
incidence of venous thromboembolism (VTE) after hip
fracture, total hip arthoplasty or multiple trauma goes
up to one third to one half [1,2]. Thromboprophylaxis
using heparin can reduce thrombembolic complications
by up to 40 to 60% [3]. During the last decades low mo-
lecular weight (LMW) heparins replaced unfractionated
heparin (UH) and became gold standard for thrombo-
prophylaxis in orthopaedic surgery [4].* Correspondence: tim.klueter@uksh.de
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unless otherwise stated.In 1956 Stinchfield and colleagues documented the ef-
fects of heparin and warfarin on bone repair. They de-
scribed that daily administration of heparin causes
attenuated fracture healing in rabbit and canine models
[5]. Street et al. analyzed the effect of LMW heparin on
fracture healing of the rabbit. Histomorphometric, histo-
logic and immunohistochemical testings demonstrated
that the bone repair was attenuated at all times in ani-
mals receiving Enoxaparin [6]. Besides LMW heparins
have been shown to cause osteoporosis when given for
longer than 8 weeks [7]. In case of fractures, pericytes
migrate from peristostal vasculation and transform into
ostogenic progenitor cells. UH and LMW heparin bind
to endothelial cells and osteoblast, reduce their activity
and prohibit neovascularisation [8]. On the other hand
decreased blood clotting due to an enlarged fracture
hematoma has a negative influence on the initial phase of
the fracture healing. Potassium channels in osteoblastshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Group distribution of 48 rats
Time point Test Quantity
Day 28 Biomechanical testing 6 rats each group
Micro CT analysis 6 rats each group
Histologic assessment
Day 49 Biomechanical testing 6 rats each group
Micro CT analysis 6 rats each group
Histologic assessment
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kalaemia, by enabling them to react on proliferative cy-
tokines. This leads to significant cytostasis and cell
distraction in the fresh hematoma [6,9]. Both mecha-
nisms, the binding of endothelial cells and osteoblasts
as well as the bleeding tendency may cause a delay of
fracture healing.
Recently, the novel oral anticoagulant rivaroxaban
(Xarelto©) was developed to safely and effectively pre-
vent VTE. Rivaroxaban inhibits coagulation factor Xa
directly by binding to its active centre. Factor Xa is the
active form of the coagulation factor thrombokinase and
is synthesised in liver. Long et al. have recently shown
that in comparison with LMW heparins rivaroxaban re-
duced the incidence of VTE by 45% without increasing
the risk of bleeding in patients with lower extremity
fractures [10]. Patients receiving rivaroxaban do not
need to undergo daily injection or regular drug monitor-
ing and therefore profit from a higher comfort and
greater compliance. During the last years oral factor Xa
inhibitors gained continuously more popularity in throm-
boprophylaxis after total hip and knee arthroplasty. It is
assumed that oral factor Xa inhibitors will be established
in thromboprophylaxis of trauma patients soon.
So far the effect of rivaroxaban on fracture healing has
not been investigated. In in vitro studies Gigi et al. have
recently revealed an inhibition of osteoblast metabolism
caused by rivaroxaban [11]. Considering these facts the
authors hypothesized that thromboprophylaxis with this
new substance would promote interfragmentary hematoma
collection and delay bone formation during fracture heal-
ing. Therefore we investigated the effect of rivaroxaban
in an established rodent fracture model, first published
by Bonnarens [12]. The application and dose is well in-
vestigated because first developments and tests were
conducted in rats [13].
Methods
Animals
Ethical approval was obtained from the regional Ethics
committee Schleswig-Holstein, Germany (V 312-72241.121-9
(8-1/09)). 48 female Wistar-rats weighing 230 ± 30 g were
obtained from the local Service Unit of the authors’ insti-
tution. The animals were kept two per cage with free ac-
cess to rat-chow and water. The lighting was maintained
on a 12-hour light-dark cycle. Analgesic treatment was ad-
ministered to all animals 4 times a day via drinking water
(100 mg/kg metamizole sodium (Novalgin®, Hoechst,
Unterschleißheim, Germany)). After the surgical pro-
cedure four groups were randomised, two groups were
treated with 3 mg rivaroxaban per kg body weight per
day together with their chow, two control groups were
only fed with chow (Table 1). The animals were eutha-
nized on day 28 or 49 after surgical procedure.Surgical procedure
Implants and surgical equipment were sterilized in an
autoclave. Sterile gowns, gloves, surgical mask and theatre
caps were used. Preoperatively each rat received 0.06 mg
buprenorphine orally. The animals were anaesthetized
with Fentanyl 0.005 mg/kg, Midazolam 2.0 mg/kg and
Medetomedine 0.15 mg/kg by intraperitoneal injections.
The rat leg was shaved and washed with chlor-hexidine.
Medial to the patella the skin was incised and the patella
dislocated to the lateral side, so that the condyles were ex-
posed. A 0.90x40 mm sterile cannula (Braun, Melsungen,
Germany) was drilled though the medullary channel using
an intercondylar approach. The sharp end was place to
the proximal end of the femur and the rest of the cannula
was cut off, so that no end extended beyond the bone.
The patella was repositioned over the knee joint and the
skin was closed with resorbable thread. A closed middia-
physeal transverse fracture was created in the right femur
by three-point bending as described by Bonnarens [12].
Anaesthesia was antagonized by intraperitoneal Naloxon
0.12 mg/kg, Flumazenil 0.2 mg/kg und Atipamezol
0.75 mg/kg. Animals were sacrificed by CO2 asphyxation
on day 28 and day 49. Bones were dissected, fixed in 4%
paraformaldehyde and stored in 70% Ethanol or used for
biomechanical testing.
Biomechanical testing
Torsional rigidity was analysed as described by Manigrasso
[14]. Testing was performed using a custom built torsional
servohydraulic testing device as described by Turner et al.
and Engesaeter et al. [15,16] using a 20 Nm reaction torque
load cell. Femurs were tested to failure at an actuator head
displacement rate of 1°/second. The peak torque and angle
at failure were measured from the torque-angle deflection
curves.
Micro CT analysis
For a detailed qualitative and quantitative 3-D evaluation,
the fracture site was examined in a micro CT scanner
(Scanco Medical AG, Bassersdorf, Switzerland) equipped
with a 70 μm focal spot microfocus X-ray tube as a source.
During scanning, the femoral bones were placed in phos-
phate buffered saline. Radiographic projections were per-
formed at 70 kV and 114 μA with a fixed integration time
Figure 1 (See legend on next page.)
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Figure 1 Photomicrography of fracture callus from rat femur. Panoramic views (1) and high magnification (20×) photomicrography (2) of
fracture healing and callus formation was illustrated using calcified bone histology technique with toluidine blue staining. The magnification
points up the remodelling zone within the fracture gap. 28 days after fracture the fracture gap (*) and a sufficient callus is noticeable with partial
bony bridging (A + B). 49 days after fracture the femurs demonstrate increased bone tissue with lamellar bone (C + D). No significant difference
could be seen between control and treatment group. Bar represents 1 mm (A1 – D1) or 100 μm (A2 – D2) respectively. pbb = partial bony
bridging; lp = lamellar part; wp = woven part.
Figure 2 Torsional rigidity. Torsional rigidity of 28-days- and 49-day-
old fractures callus species was detected for control and rivaroxaban
treated rats. Rigidity raised between day 28 and 49, but no significant
difference was measured between control and treatment group. n = 6
(each group).
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mounted on a turntable shifted automatically in an
axial direction over 180°, taking 500 projections. Three-
dimensional images were stored in 3-D arrays with an iso-
tropic voxel size of 16 μm and a pixel size of 1024x1024.
The region of interest (ROI) covered a total range of
8.4 mm (encompassing 4.2 mm proximal and distal to the
fracture line). For quantitative analysis of bone formation
within the ROI Scano Evaluation software (Scano Medical,
Brüttisellen, Switzerland) was used to obtain the volume
of interest. Depending on the grey threshold these vol-
umes were reflected to highly mineralised tissue (bone, 33
to 60%) and low mineralised tissue (callus, 17.5 to 33%).
Tissue mineralized density was calculated by dividing the
volume of the mineralised callus by the tissue’s density.
Due to technical problems the results of 3 rats treated for
49 days were deleted somehow. When this error was no-
ticed, samples could not be scanned again.
Preparation of specimens
To illustrate the micro-architecture of the callus, unde-
calcified bone histology was performed. The bones were
fixed in 10% neutral buffered formalin for 14 days at
room temperature, dehydrated with ascending concen-
tration of ethanol and embedded in methylmetacrylate
for 5 days at 4°C. Afterwards tissue was soaked in methyl-
methacrylat monomer, nonylphenyl-polyethyleneglycol acet-
ate and azoisobutyronitrile (all Sigma-Aldrich, St. Louis,
USA). The blocks were released from the glass vials and
undecalcified sections of 40 μm were sawed and grinded
using an EXAKT diamond saw system (Exakt, Norderstedt,
Germany).
Histologic assessment
For histologic staining sections were lubricated with
0.1% formic acid for 2 minutes and washed with aqua
afterwards. The samples were immersed in 20% methanol
for 1 hour and stained with toluidine blue or hematoxylin
and eosin.
Statistical analysis
Statistical analysis was performed using a standard soft-
ware application (SPSS Inc., Chicago, IL, USA). Results
of CT scanning and torsional testing were expressed as
the means ± standard deviation of tested groups. The differ-
ent groups were tested for normality using Kolmogorov-Smirnov test. Statistical significance was evaluated using
one-way Anova with Bonferroni correction. Sample distri-
bution for torsional testing and CT scanning were illus-
trated with Box and whisker plots.
Results
All animals recovered quickly after the surgical proce-
dures and fully mobilized within two days. No signs of
pain or dysfunction in the physical motion was recog-
nized. No animal had to be excluded because of death,
implant dislocation or soft tissue infection.
Histology
For assessment of fracture healing and callus formation
we used a standard calcified bone histology technique.
Thereby we could illustrate the cellular and mineralised
components of the callus in the longitudinal axis, which
provides vital information on bone turnover or bone for-
mation and resorption. 28 days after closed femur frac-
ture the fracture gap was still visible and sufficient callus
had arisen (Figure 1). Tolouidine blue staining showed
partial bony bridging of the gap in the 28 days group
and the bridging increased 49 days after fracture. During
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the amounts of newly formed bone increased between
day 28 and 49. Bony callus consists of woven and lamel-
lar bone, and here the lamellar part increased and the
woven part decreased.
No significant difference in fracture healing could be
identified in either comparison group after 28 or 49 days.
Over all the callus sizes showed great variability amongst
all groups.
Biomechanical analysis
The operated femurs were analysed for torsional rigidity
28 and 49 days after the surgical procedure. Parameters
such as torsional rigidity calculated from torsion tests
are convenient for determining the structural and materialFigure 3 3D imaging of the interfragmentary zone. (A) Tissue volumes
determined by micro-CT analysis. During Fracture healing volume of bone
volume decreased from 42.17 mm3 to 9.7 mm3. B + C The images show fe
(B) 28-days-old femurs fracture reveals a fracture gap a sufficient callus (gre
decreased and formatted to mineralised bone tissue.properties of the healing tissue. After 4 weeks of rivaroxa-
ban diet the femur callus showed no significant difference
in torsional rigidity compared to the control group
(0.0154 ± 0.0039 N/m2 versus 0.0141 ± 0.0056 N/m2;
p = 0.81). Even after 7 weeks of rivaroxaban treatment
rigidity did not change significantly (Figure 2).
Micro CT scan of interfragmentary zone
The callus volume was determined from 4.2 mm proximal
to 4.2 mm distal of the fracture gap by micro CT scanning.
During fracture healing bone tissue increaed in rivaroxa-
ban treated rats from 65.9 ± 8.1 mm3 to 89.2 ± 2.7 mm3
(p = 0.06), whereas callus volume decreased from 42.17 ±
5.3 mm3 to 9.7 ± 3.1 mm3 (p = 0.04; Figure 3). After
28 days we detected an insignificant increase of callusof defined fracture zone of rats’ femur treated with rivaroxaban was
tissue increased from 65.9 mm3 to 89.2 mm3. On the other hand callus
murs of rivaroxaban treated rats 28 and 49 days after femur fracture.
en). (C) 49 days after fracture the volume of callus tissue (green) had
A B
Figure 4 Tissue volumes. (A) Femur fracture callus volume of control and rivaroxaban treated rats after 28 and 49 days was detected by micro
CT-scan. Treated rats showed increase of callus volume compared to control group. 49 days after fracture callus was almost transformed to bone
tissue. (B) Bone volume decreased from day 28 to day 49, but no significant differences could be seen between the groups. n = 6 (28 days);
n = 3 (49 days).
Figure 5 Tissue mineral density. Tissue mineral density of rat
femur callus was quantified by micro CT-scan 28 and 49 days after
femur fracture. The rivaroxaban treatment group revealed marginal
increase compared to control group. n = 6 (28 days); n = 3 (49 days).
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treatment compared to the control animals (28.37 ±
13.42 mm3 versus 42.17 ± 11.98 mm3; p = 0.12). After
49 days the callus was almost completely transformed
to bony tissue, thus no significant alteration between
both groups could be determined (Figure 4A).
No significant difference could be seen in bone volume
between the groups at both points of time (69.0 mm3 ±
17.0 versus 65.9 mm3 ± 19.8 and 75.2 mm3 ± 4.3 versus
89.15 mm3 ± 3.9) (Figure 4B).
Tissue mineral density (TMD)
To quantify the formation of the callus we analysed the
TMD which was generated by micro CT scans within
the defined area. After 28 days of rivaroxaban treatment
we documented a marginal increase of the TMD com-
pared to the control specimens (0.057 ± 0.017 mg/cm3
versus 0.055 ± 0.012 mm3; p = 0.31). A similar trend was
ascertained for 49-day-old callus (0.08 ± 0.008 mg/cm3
versus 0.076 ± 0.007 mg/cm3; p =0.86), but both effects
were statistically insignificant (Figure 5).
Discussion
Previous studies indicate a delay of callus remodelling
due to thromboprophylaxis with UH and LMW heparin
[9,17]. So far there is no study which investigated the ef-
fect of the new oral Factor Xa inhibitor rivaroxaban on
fracture healing. Considering the fact that this anti-
coagulant is finding its way into treatment of trauma pa-
tients, it is indispensable to know its influence on thehealing bone. Due to the complexity of interaction of the
diverse cell types and tissues in vitro reproducibility of the
bone healing process is not convincing. Therefore we uti-
lised a classic established rodent fracture model [12].
In contrast to previous studies with heparins no delay of
fracture healing relating to rivaroxaban treatment could
be determined in the present study. Daily administration
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insignificantly. To evaluate the progress of bone healing,
we analysed callus by histological staining and docu-
mented a comparable repair process concerning the pat-
terns of bone bridging, including periosteal, endosteal,
intercortical patterns and mineralisation [18] We did not
identify significant differences within the two groups at
the same points of time. To quantify the callus mineralisa-
tion we performed micro CT scans as a valid assessment
for bone stiffness. Previous studies revealed that TMD has
the same validity for stiffness as the torsional righty
[19-21]. The high resolution scan of the callus microstruc-
ture showed a small and not significant increase of TMD
after rivaroxaban treatment. These results correlate with
an in vitro study with cultured osteoblast which demon-
strated a dose-dependent transient inhibition of osteoblast
metabolism by rivaroxaban but no effect on mineralisation
[11]. As another parameter for bone stiffness we measured
the bone volume which did not increase significantly.
The torsional rigidity is a scientifically recognized stand-
ard to evaluate fracture healing [6,20,22]. Our study indi-
cates that the torsional rigidity did not decrease after
application of the oral anticoagulant. In contrast to that in
previous studies LWM heparins result in a decrease of
torsional stiffness and lower energy to fracture [6]. The
authors explained this effect by binding of enoxaparin
to vascular endothelium which disrupts callus vascular
assembly and also by an increase of interfragmentary
hematoma and subsequent cytotoxic effects on cells of
the medullary callus. Due to technical problems we
could not reach the minimal quantity to perform statis-
tical analysis for the 49-days-old treatment group. Eventu-
ally the existing results could not justify further animal
experimentation to reach statistical significance.
Taken together we could not document a negative effect
in bone stiffness after rivaroxaban treatment. The higher
callus volume on day 28 in combination with equal bone
volume and tissue mineral density seems not to have an
influence on the stability of the fracture.
Conclusion
In the present study we could for the first time demon-
strate that thromboprophylaxis with rivaroxaban does
not downgrade fracture healing in a rodent fracture
model. Because of the low number of random samples,
we are aware that this study is not powerful enough to
give a general recommendation for the use of oral factor
Xa inhibitor in case of trauma patients. Nevertheless
considering the fact that LMW heparin, the gold stand-
ard for thromboprophylaxis, delays fracture healing sig-
nificantly, rivaroxaban might be an improved alternative.
The indications in prevention and treatment of throm-
bosis, particularly in trauma surgery, need further evalu-
ation covering all aspects of bone repair.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TK drafted the manuscript, participated in its design and performed the
statistical analysis. MW carried out the surgical procedures and participated
in its design and coordination. SB carried out the surgical procedures and
the biomechanical testing and performed the statistical analysis. LM carried
out the surgical procedures and carried out the biomechanical testing. SF
conceived of the study and carried out the histologic assessment. NS carried
out the histologic staining and participated in its design and coordination.
YA carried out the histologic staining. TP participated in the design of the
study and performed the statistical analysis. DV participated in the biomechanical
testing. AS conceived of the study and participated in its design. SL designed
the study, participated in its coordination and helped to draft the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
This work was supported by the AO-Foundation, by a grant from the
Interdisciplinary Centre for Clinical Research (IZKF) within the faculty of
Medicine at the RWTH Aachen University (T9-3; T9-5; T11-3) and in part by
the Excellence Initiative of the German federal and state governments.
We thank Dr Dophie Fargher at Starship Hospital, Auckland, NZL, for editing
and proofreading the article.
Author details
1Department of Trauma Surgery, University Medical Center of
Schleswig-Holstein, Campus Kiel, Germany. 2Department of Anatomy and
Cell Biology, RWTH Aachen University, Aachen, Germany. 3Department of
Maxillo-Facialy, University Medical Center of Schleswig-Holstein, Campus Kiel,
Germany. 4Department of Trauma Surgery, University of Kiel,
Arnold-Heller-Strasse 3, 24105 Kiel, Germany.
Received: 7 September 2014 Accepted: 13 February 2015
References
1. Haake DA, Berkman SA. Venous thromboembolic disease after hip surgery:
risk factors, prophylaxis, and diagnosis. Clin Orthop Relat Res.
1989;242:212–31.
2. Salzman EW, Harris WH. Prevention of venous thromboembolism in
orthopaedic patients. J Bone Joint Surg Am. 1976;58(7):903–13.
3. Handoll HH, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Milne AA, Gillespie WJ.
Heparin, low molecular weight heparin and physical methods for preventing
deep vein thrombosis and pulmonary embolism following surgery for hip
fractures. Cochrane Database Syst Rev. 2002;4:Cd000305.
4. Palmer AJ, Koppenhagen K, Kirchhof B, Weber U, Bergemann R. Efficacy and
safety of low molecular weight heparin, unfractionated heparin and warfarin
for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of
randomised clinical trials. Haemostasis. 1997;27(2):75–84.
5. Stinchfield FE, Sankaran B, Samilson R. The effect of anticoagulant therapy
on bone repair. J Bone Joint Surg Am. 1956;38-a(2):270–82.
6. Street JT, McGrath M, O’Regan K, Wakai A, McGuinness A, Redmond HP.
Thromboprophylaxis using a low molecular weight heparin delays fracture
repair. Clin Orthop Relat Res. 2000;381:278–89.
7. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337(10):688–98.
8. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F.
Cellular effects of heparin on the production and release of tissue factor
pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb
Vasc Biol. 1999;19(9):2251–62.
9. Hak DJ, Stewart RL, Hazelwood SJ. Effect of low molecular weight heparin
on fracture healing in a stabilized rat femur fracture model. J Orthop Res.
2006;24(4):645–52.
10. Long A, Zhang L, Zhang Y, Jiang B, Mao Z, Li H, et al. Efficacy and safety of
rivaroxaban versus low-molecular-weight heparin therapy in patients with
lower limb fractures. J Thrombosis Thrombolysis. 2014;38(3):299–305.
11. Gigi R, Salai M, Dolkart O, Chechik O, Katzburg S, Stern N, et al. The effects
of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell
line SaOS2. Connect Tissue Res. 2012;53(6):446–50.
12. Bonnarens F, Einhorn TA. Production of a standard closed fracture in
laboratory animal bone. J Orthop Res. 1984;2(1):97–101.
Klüter et al. BMC Musculoskeletal Disorders  (2015) 16:79 Page 8 of 813. Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer
KH, et al. In vitro and in vivo studies of the novel antithrombotic agent
BAY 59–7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost.
2005;3(3):514–21.
14. Manigrasso MB, O’Connor JP. Characterization of a closed femur fracture
model in mice. J Orthop Trauma. 2004;18(10):687–95.
15. Engesaeter LB, Ekeland A, Langeland N. Methods for testing the mechanical
properties of the rat femur. Acta Orthop Scand. 1978;49(6):512–8.
16. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial.
Bone. 1993;14(4):595–608.
17. Sarahrudi K, Kaiser G, Thomas A, Michel M, Wolf H, Mousavi M, et al. The
influence of low molecular weight heparin on the expression of osteogenic
growth factors in human fracture healing. Int Orthop. 2012;36(5):1095–8.
18. Marsh D. Concepts of fracture union, delayed union, and nonunion. Clin
Orthop Relat Res. 1998;355 Suppl:S22–30.
19. Markel MD, Wikenheiser MA, Morin RL, Lewallen DG, Chao EY. Quantification
of bone healing: comparison of QCT, SPA, MRI, and DEXA in dog
osteotomies. Acta Orthop Scand. 1990;61(6):487–98.
20. Nyman JS, Munoz S, Jadhav S, Mansour A, Yoshii T, Mundy GR, et al. Quantitative
measures of femoral fracture repair in rats derived by micro-computed
tomography. J Biomech. 2009;42(7):891–7.
21. Tiedeman JJ, Lippiello L, Connolly JF, Strates BS. Quantitative
roentgenographic densitometry for assessing fracture healing. Clin Orthop
Relat Res. 1990;253:279–86.
22. Gabet Y, Muller R, Regev E, Sela J, Shteyer A, Salisbury K, et al. Osteogenic
growth peptide modulates fracture callus structural and mechanical
properties. Bone. 2004;35(1):65–73.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
